{"result": "(\"entity\"<|>GISSI-PREVENZIONE TRIAL<|>EVENT<|>The GISSI-Prevenzione Trial was a clinical trial conducted in 1999 involving 11,324 male patients with recent myocardial infarction, aimed at assessing the effects of EPA+DHA on coronary heart disease mortality.)\n##\n(\"entity\"<|>ESTUDIO JELIS<|>EVENT<|>The Estudio JELIS was a clinical trial conducted in 2007 with nearly 19,000 dyslipidemic patients, evaluating the effects of statins combined with EPA on cardiovascular risk.)\n##\n(\"entity\"<|>OMEGA<|>EVENT<|>The OMEGA study, conducted in 2010, involved 3,851 patients with a history of myocardial infarction, assessing the effects of EPA and DHA on sudden cardiac death and cardiovascular events.)\n##\n(\"entity\"<|>ALPHA-OMEGA<|>EVENT<|>The ALPHA-OMEGA study, also conducted in 2010, involved approximately 4,800 patients with a history of myocardial infarction, evaluating the effects of EPA+DHA on triglyceride levels and cardiovascular events.)\n##\n(\"entity\"<|>EPA<|>ORGANIZATION<|>EPA refers to Eicosapentaenoic acid, an omega-3 fatty acid studied for its effects on cardiovascular health.)\n##\n(\"entity\"<|>DHA<|>ORGANIZATION<|>DHA refers to Docosahexaenoic acid, another omega-3 fatty acid that is important for cardiovascular health and is often studied alongside EPA.)\n##\n(\"relationship\"<|>GISSI-PREVENZIONE TRIAL<|>EPA<|>The GISSI-Prevenzione Trial assessed the effects of a daily dose of EPA+DHA on coronary heart disease mortality among participants<|>8)\n##\n(\"relationship\"<|>ESTUDIO JELIS<|>EPA<|>The Estudio JELIS evaluated the effects of a combination of statins and EPA on cardiovascular risk in dyslipidemic patients<|>8)\n##\n(\"relationship\"<|>OMEGA<|>EPA<|>The OMEGA study investigated the effects of a daily dose of EPA and DHA on sudden cardiac death and cardiovascular events<|>8)\n##\n(\"relationship\"<|>ALPHA-OMEGA<|>EPA<|>The ALPHA-OMEGA study examined the effects of EPA+DHA on triglyceride levels and cardiovascular events in patients with a history of myocardial infarction<|>8)\n##\n(\"relationship\"<|>GISSI-PREVENZIONE TRIAL<|>DHA<|>The GISSI-Prevenzione Trial also involved the assessment of DHA alongside EPA for its effects on coronary heart disease mortality<|>8)\n##\n(\"relationship\"<|>ESTUDIO JELIS<|>DHA<|>The Estudio JELIS included the evaluation of DHA in combination with statins for its impact on cardiovascular risk<|>8)\n##\n(\"relationship\"<|>OMEGA<|>DHA<|>The OMEGA study assessed the effects of DHA in conjunction with EPA on sudden cardiac death and cardiovascular events<|>8)\n##\n(\"relationship\"<|>ALPHA-OMEGA<|>DHA<|>The ALPHA-OMEGA study evaluated the effects of DHA alongside EPA on triglyceride levels and cardiovascular events<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: marinos. Dentro del or-                              pescado ≥ 1 vez/semana, y de que el 40% estuvie-\nganismo humano, los ácidos grasos ω-3 son compo-                                   ra tratado con estatinas podría haber dificultado\n                                                                                   la detección del efecto59.\nnentes estructurales de los fosfolípidos de membrana                            •  En el estudio PREDIMED, basado en la observa-\nde tejidos, en especial de la retina, cerebro y esperma-                           ción de aquellos que consumen > 500 mg de\ntozoides53.                                                                        EPA-DHA, solo se objetivó beneficio para el infarto\n   Los estudios de intervención con AGP-ω3 sobre el                                mortal (RR: 0,537; IC96%: 0,29- 0,98), pero no\nriesgo cardiovascular no han sido homogéneos, debi-                                para el infarto no mortal o la muerte súbita60.\ndo a la heterogeneidad de las poblaciones de estudio,\ndel modelo de intervención y de las variables principa-                         Los abundantes metanálisis sobre este tema no lle-\nles de evaluación. Podemos destacar los siguientes en-                       gan a resultados concluyentes con respecto a ECV en\nsayos clínicos7 :                                                            general, si bien se detecta una protección consistente\n                                                                             frente a mortalidad cardiaca61-65. Los resultados nulos\n   •   GISSI-Prevenzione Trial (1999). 11.324 pacientes                      pueden deberse a varios factores, entre los que destaca:\n       varones con infarto de miocardio reciente se alea-                    la mejora de las guías de actuación en la prevención\n       torizadon a recibir 882 mg/día de EPA+DHA fren-                       secundaria, con una mejor adherencia a la dieta, el tra-\n       te a tratamiento habitual. Tras una media de 3,5                      tamiento con estatinas o con antigregantes plaqueta-\n       años de seguimiento, se observó una reducción                         rios o bien porque en poblaciones que hayan incremen-\n       significativa de muerte por enfermedad coronaria\n       y muerte súbita cardiaca54.                                           tado el consumo de pescados o de cápsulas de ω-3, la\n\n                                                                             adición de un mayor consumo de AGP-ω3 no va a tener\n   •   Estudio JELIS (2007). Cerca de 19.000 pacientes                       un efecto aditivo sobre el riesgo cardiovascular.\n       dislipémicos fueron aleatorizados a recibir estatinas                    De manera general podemos decir que, en preven-\n       frente a una combinación de estatinas + 1,8 g/día                     ción primaria, el mayor consumo de AGP-ω3 tiene un\n       de EPA. A los 5 años de seguimiento, los pacientes                    escaso efecto protector (10-15%) sobre la enfermedad\n       en prevención primaria tratados con EPA presen-                       coronaria66-68. En prevención secundaria, el consumo\n       taron   una    reducción      significativa    del  19%     de        de AGP-ω3, procedentes del pescado, puede conferir\n       eventos isquémicos y del 23% en prevención se-\n       cundaria55.                                                           un efecto protector mayor, en relación a sufrir un epi-\n                                                                             sodio de muerte súbita o de reinfarto mortal69, 70.\n   •   OMEGA (2010). En este estudio, 3.851 pacientes                           Las acciones de los ácidos grasos            ω-3 procedentes\n       con un infarto de miocardio previo fueron aleato-                     del pescado se establece a diferentes niveles: en el me-\n       rizados a una dosis de 840 mg/día de EPA y DHA                        tabolismo de las lipoproteínas, en la formación de eico-\n       frente a placebo. No se observó efecto sobre la                       sanoides y en los mecanismos de regulación de la\n       muerte súbita cardiaca ni nuevos eventos cardio-                      trombogénesis y la función endotelial71. Varios estu-\n       vasculares tras un año de seguimiento56.                              dios han demostrado que la ingestión de ácidos grasos\n   •   ALPHA-OMEGA (2010). Aproximadamente 4.800                             ω-3 reduce las concentraciones de triglicéridos de una\n       pacientes con historia de infarto de miocardio                        manera dosis dependiente, básicamente disminuyendo\n       fueron aleatorizados a 376 mg/día de EPA+DHA                          la síntesis de las lipoproteínas de muy baja densidad\n       frente a ALA (1,9 g/día) o grupos combinados.                         (VLDL)72, lo que le hace tener un papel destacado en el\n       Tras 3,3 años de seguimiento, no se observó nin-                      tratamiento de las hipertrigliceridemias o en las dislipe-\n       gún efecto de las intervenciones sobre eventos\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}